Key Insights• According to the research report, "Spain EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Spain EPA & DHA Market is anticipated to grow at more than 8.36% CAGR from 2026 to 2031. The Spanish EPA & DHA market is steadily expanding as the country faces rapid population aging, a significant burden of circulatory disease, and growing consumer adoption of food supplements through pharmacies and supermarkets. According to INE, Spain's population reached a record 49,570,725 on January 1, 2026, driven by net immigration. INE's provisional 2024 cause-of-death statistics show that Spain recorded 433,547 deaths, with diseases of the circulatory system accounting for 26.1% of the total, a rate of 231.8 per 100,000 inhabitants, while ischemic heart disease alone caused 26,851 deaths, down 3.2% from 2023. Deaths rose a further 2.5% to 446,982 in 2025, according to INE's provisional estimates. Spain has one of the highest fish consumption levels in Europe, yet changing dietary habits among younger generations are reducing oily fish intake, creating a growing gap that supplements and fortified foods are positioned to fill. The growing clinical burden is placing additional pressure on Spain's National Health System and the consumer health sector to strengthen access to EPA and DHA through supplements, prescription omega-3 medicines, infant nutrition, and clinical nutrition.• Spain's EPA & DHA market is characterized by a dynamic ecosystem comprising domestic omega-3 ingredient manufacturers, pharmaceutical laboratories, pharmacy and parapharmacy networks, supermarket private labels, infant formula producers, and a fast-growing pet food sector.

Spain is home to Solutex, a Madrid-based producer of natural omega-3 concentrates from fish and algae oils for pharmaceutical and food supplement applications, which operates a manufacturing plant in Mallén, Aragón. Distribution is led by more than 22,000 community pharmacies, alongside supermarket chains such as Mercadona, Carrefour, and Lidl, whose private-label omega-3 ranges have broadened household penetration, and online platforms such as Amazon and PromoFarma. Domestic infant formula producers such as Ordesa (Blemil) compete with multinational companies including Nestlé, Danone, and Hero.• Regulatory oversight for EPA and DHA products in Spain is shaped by European Union legislation implemented through national rules. Food supplements are regulated under Directive 2002/46/EC, transposed through Royal Decree 1487/2009, and must be notified to the competent health authorities before marketing, with the Spanish Agency for Food Safety and Nutrition (AESAN) coordinating food safety policy. Health claims are governed by Regulation (EC) No. 1924/2006 and Regulation (EU) No. 432/2012, infant formula must contain DHA under Delegated Regulation (EU) 2016/127, and algal and krill oils require EU Novel Food authorization. Prescription omega-3 medicines are authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS) or through the European Medicines Agency, with Vazkepa (icosapent ethyl) approved and sold in Spain and now commercialized in Europe by Recordati under its June 2025 agreement with Amarin.Market Outlook• A defining characteristic of Spain's EPA & DHA market is the coexistence of pharmacy-led premium brands and high-volume supermarket private labels.

Pharmacies offer high-concentration triglyceride fish oils, krill oil, algal DHA, and combination products recommended by pharmacists and physicians, while supermarket chains provide affordable fish oil capsules that have expanded access to price-sensitive consumers. Spanish ingredient manufacturers are also contributing to innovation, with Solutex developing concentrated omega-3 bioactive ingredients from fish and algae oils using supercritical fluid technology for pharmaceutical and supplement customers worldwide. Simultaneously, prescription EPA has gained a foothold in cardiovascular risk management, with Spain listed among the European markets where Vazkepa is approved and sold, and Recordati's European commercial network expected to support further adoption from 2025.• The market also reflects Spain's growing emphasis on healthy aging and cardiovascular prevention. Spanish health authorities and scientific societies continue to promote the Mediterranean diet, including regular fish consumption, as a cornerstone of cardiovascular health, providing a supportive backdrop for omega-3 messaging. In infant nutrition, INE's provisional estimates show that Spain recorded 321,164 births in 2025, up 1.0% from 2024, breaking a decade of consecutive declines, while the share of births to mothers aged 40 or older rose to 10.4%. The mandatory DHA requirement for infant formula ensures a stable baseline of demand for high-purity fish and algal DHA, while domestic producers compete on premium formulations.Market DynamicsDriver: Rapid demographic aging and circulatory disease burden supported by growing supplement adoptionSpain's EPA & DHA market is primarily driven by demographic aging and the high prevalence of circulatory disease.

Diseases of the circulatory system accounted for 26.1% of deaths in Spain in 2024, according to INE, and ischemic heart disease caused 26,851 deaths. Spain has one of the highest life expectancies in the world, and the share of the population aged 65 and older continues to rise, increasing demand for products that support cardiovascular, cognitive, eye, and joint health. Supplement adoption has grown steadily, supported by pharmacist recommendation and the expansion of supermarket private labels. EU-authorized health claims enable EPA and DHA products to communicate benefits for normal heart function, blood triglyceride levels, and, for DHA, normal brain function and vision. As awareness of prevention continues to grow, pharmacies and supermarkets are witnessing sustained demand for EPA and DHA products.Challenge: Price competition, raw material volatility, and declining oily fish intake among younger consumersOne of the principal challenges facing Spain's EPA & DHA market is intense price competition from supermarket private labels, which compresses margins for branded manufacturers and pharmacy brands. At the same time, raw material costs remain volatile.

Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early on August 1, 2025, and again on August 12, 2026. Additionally, while Spain's traditional diet includes high fish consumption, younger generations are eating less fish, and the perception that the Mediterranean diet already provides sufficient omega-3 can limit supplement uptake. The absence of harmonized EU maximum levels for EPA and DHA in supplements also creates regulatory complexity across markets. Together, these factors require continuous investment in consumer education, quality differentiation, and supply chain resilience.Trend: Domestic omega-3 innovation, algal oil adoption, and rapid growth of pet nutritionSpain is experiencing a significant shift toward innovative and sustainable omega-3 solutions supported by domestic ingredient expertise and consumer interest in plant-based nutrition. Solutex's expansion of its Mallén facility is supporting the production of concentrated omega-3 ingredients from both fish and algae oils, while algal DHA is gaining traction in prenatal and vegetarian ranges, supported by ingredient innovation such as dsm-firmenich's life'sDHA B54-0100, launched in October 2024. Simultaneously, the pet sector is emerging as a major demand pocket.

Spain's pet population reached approximately 15.17 million companion animals in 2025, including 7.56 million dogs and 5.62 million cats, up around 14% from 2021, according to preliminary results of the national animal protection statistics. The Spanish pet food market grew 6.1% to EUR 2,118 million in 2025, according to ANFAAC, with premium foods and supplements incorporating fish oil gaining share.Policies• Food Supplement Notification (Royal Decree 1487/2009): Food supplements containing EPA and DHA are regulated under Directive 2002/46/EC and Royal Decree 1487/2009. Products must be notified to the competent health authorities before marketing, with AESAN coordinating food safety policy and regional authorities responsible for enforcement.• EU Nutrition and Health Claims Regulation: Health claims for EPA and DHA are governed by Regulation (EC) No. 1924/2006 and Regulation (EU) No. 432/2012, authorizing claims for normal heart function, blood triglyceride levels, blood pressure, and DHA contributions to normal brain function, vision, and maternal and infant development.• Infant Formula DHA Requirement: Under Delegated Regulation (EU) 2016/127, infant formula and follow-on formula must contain DHA at 20–50 mg per 100 kcal, ensuring stable demand for high-purity fish and algal DHA among domestic and multinational formula producers.• Novel Food Authorization: Krill oil and algal oils require authorization under Regulation (EU) 2015/2283 and listing in the Union list of novel foods. Schizochytrium sp. (CABIO-A-2) oil was authorized through Implementing Regulation (EU) 2024/2101 in July 2024, broadening the range of approved algal DHA suppliers.• AEMPS Medicine Authorization and Reimbursement: Prescription omega-3 medicines are authorized by AEMPS or centrally by the European Medicines Agency, with pricing and reimbursement within the National Health System determined by the Ministry of Health, influencing access to prescription EPA and omega-3-acid ethyl esters.Segment AnalysisSpain EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Spain, particularly in infant formula, prenatal supplements, and cognitive and eye health products. DHA is mandatory in infant formula, and algal DHA is increasingly used in prenatal ranges.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Spain, driven by prescription icosapent ethyl and increasing interest in high-EPA concentrates for cardiovascular health and inflammation-related wellness.Spain EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Spain due to its cost-effectiveness and broad consumer familiarity, with domestic producers such as Solutex supplying concentrated omega-3 ingredients.• Algae Oil represents the fastest-growing source category in Spain, driven by infant formula use, prenatal supplements, and demand for sustainable and contaminant-free omega-3.• Krill Oil is a premium source category positioned for absorption and smaller capsule size, sold primarily through pharmacies and online channels.• Other Marine Sources hold a niche position in the Spanish market, including cod liver oil, salmon oil, and calamari oil, primarily used in specialty supplements and pet nutrition.Spain EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Spain, distributed through pharmacies, parapharmacies, supermarkets, and online platforms.• Infant Formula represents a strategically important application segment, with DHA mandatory in all formulas. Births rose 1.0% to 321,164 in 2025, providing modest volume support.• Pharmaceuticals represent an important application segment, including prescription icosapent ethyl and omega-3-acid ethyl esters, with Recordati assuming commercialization of Vazkepa in Europe from 2025.• Food & Beverages encompasses omega-3-enriched milk, eggs, bread, and canned fish products, supported by Mediterranean diet positioning.• Clinical Nutrition & Medical Foods includes fish oil-based lipid emulsions for parenteral nutrition and enteral formulas used in hospitals and long-term care.• Pet Nutrition represents the fastest-growing application segment in Spain, supported by a pet population of approximately 15.17 million in 2025 and a pet food market of EUR 2,118 million, up 6.1%, according to ANFAAC.Major EPA & DHA Manufacturers Operating in Spain• Solutex, dsm-firmenich, KD Pharma Group, Recordati, Amarin, Uriach (Aquilea), Arkopharma, Solgar, Ordesa, Nestlé, Danone, Hero, Fresenius Kabi, and Aker BioMarine are leading players in the Spanish EPA & DHA market, offering concentrated omega-3 ingredients, finished supplements, prescription omega-3 medicines, DHA-fortified infant formula, and clinical nutrition products.

Their strong presence, pharmacy partnerships, scientific support programs, and relationships with healthcare professionals have driven adoption across the Spanish market.• The market is also supported by supermarket private-label producers, contract manufacturers, ingredient distributors, and pet food producers that provide formulation, encapsulation, and distribution support. With domestic omega-3 ingredient expertise and a growing pet sector, Spain remains an important European omega-3 market.Spain EPA & DHA Supply and Pricing Economics• EPA and DHA products in Spain represent value-added nutritional and pharmaceutical products whose pricing depends on source, concentration, chemical form, certification, and channel. Pricing varies considerably between supermarket private labels, pharmacy brands, krill oil, and algal oil.• Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, according to GOED, but the reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on raw material prices.• Supplements are paid out-of-pocket, while prescription omega-3 medicines are reimbursed by the National Health System only for approved indications.• Supermarket private labels exert continuous downward pressure on mass-market pricing, while algal oil and krill oil command a premium.Market Outlook by Consumer Health Spending and Supply Infrastructure• Spain's EPA & DHA market growth is strongly linked to demographic aging, consumer health spending, and the strength of the pharmacy and supermarket channels, although private-label price competition and raw material volatility remain significant factors influencing profitability.• Private consumer spending drives the supplement and pet nutrition segments, while the mandatory DHA requirement in infant formula provides a stable demand base and prescription EPA supports the pharmaceutical segment.• The future growth opportunity for EPA and DHA in Spain depends on consumer education on the omega-3 intake gap among younger generations, continued innovation by domestic ingredient manufacturers, expansion of algal omega-3, and growth of the pet nutrition segment. Greater integration of pharmacist-led prevention and healthy aging programs will likely become key strategies for long-term market development. Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.